TNF and inflammatory bowel disease: Vedolizumab therapy is indicated in the treatment of moderate or severe UC and Crohn’s disease worldwide, whereas in our country, vedolizumab is a treatment alternative in IBD patients refractory to anti-TNF treatments or who can not receive these treatments due to side effects.